早期活动性类风湿关节炎患者以低疾病活动度或DAS缓解为治疗目标的比较
比较133例以DAS≤2.4(低疾病活动度)为目标的早期活动性RA患者与175例以DAS<1.6(缓解)为目标的早期RA患者的5年结局。两组DAS下降、功能能力和影像学损伤进展相似,但DAS<1.6组更多患者达到DAS<1.6、Boolean缓解和停药后DAS缓解。
要点
- 以DAS<1.6为目标与第1年达到DAS<1.6(OR 3.04)和Boolean缓解(OR 3.03)相关。
- 以DAS<1.6为目标与第5年停药后DAS缓解相关(OR 3.77)。
- 两组DAS下降、功能能力和影像学损伤进展随时间相似。
核心结论
- 在开始接受可比改善病情抗风湿药联合泼尼松治疗的早期活动性RA患者中,后续以DAS<1.6为目标治疗与以DAS≤2.4为目标治疗相比,随时间推移的临床和影像学结局相似;但DAS<1.6目标组更多患者达到缓解和停药后缓解。
研究设计与样本
- 比较133例以DAS≤2.4为目标的早期活动性RA患者(1987年标准,起始甲氨蝶呤、柳氮磺吡啶和逐渐减量高剂量泼尼松,来自BeSt研究第3组)与175例以DAS<1.6为目标的早期RA患者(起始甲氨蝶呤和逐渐减量高剂量泼尼松,选自IMPROVED研究中符合BeSt研究入选标准者)的5年结局。
主要发现
- 基线时DAS<1.6目标组患者疾病较DAS≤2.4目标组更轻(平均DAS 4.1±SD 0.7 vs 4.4±0.9,p=0.012)且影像学损伤更少。
- 两组随时间DAS下降、功能能力和影像学损伤进展相似。
- 两组达到DAS≤2.4的患者百分比相似,但DAS<1.6目标组更多患者达到DAS<1.6和停药后DAS缓解。
- 以DAS<1.6为目标治疗与第1年达到DAS<1.6(OR 3.04,95%CI 1.64至5.62)和Boolean缓解(OR 3.03,95%CI 1.45至6.33)相关,并与第5年停药后DAS缓解相关(OR 3.77,95%CI 1.51至9.43)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare outcomes of targeted treatment aimed at either low disease activity or remission in patients with early active rheumatoid arthritis (RA). METHODS: Five-year outcomes were compared in 133 patients with early active RA (1987), starting with methotrexate, sulfasalazine and tapered high dose of prednisone (arm 3 of the BehandelStrategieën (Treatment Strategies for Rheumatoid Arthritis) (BeSt) study), targeted at Disease Activity Score (DAS) ≤2.4 (low disease activity), and 175 patients with early RA, starting methotrexate and tapered high dose of prednisone, targeted at DAS <1.6 (selected from IMPROVED study who would have fulfilled inclusion criteria of the BeSt study). Association of treatment target with outcomes DAS <1.6, Boolean remission at year 1 and drug-free DAS remission (DFR) at year 5 were analysed by logistic regression analysis. RESULTS: At baseline, DAS <1.6 steered patients had a milder disease than DAS ≤2.4 steered patients (mean DAS 4.1±SD 0.7vs4.4±0.9, p=0.012) and less radiological damage. DAS decrease, functional ability and radiological damage progression over time were similar in both patient groups. DAS ≤2.4 was achieved in similar percentages in both patient groups, but more DAS <1.6 steered patients achieved DAS <1.6 and DFR. DAS <1.6 steered treatment was associated with achieving DAS <1.6 (OR 3.04 (95% CI 1.64 to 5.62)) and Boolean remission (3.03 (1.45 to 6.33)) at year 1 and DFR at year 5 (3.77 (1.51 to 9.43)). CONCLUSIONS: In patients with early active RA who start with comparable disease-modifying antirheumatic drug+prednisone combination therapy, subsequent DAS <1.6 steered treatment is associated with similar clinical and radiological outcomes over time as DAS ≤2.4 steered treatment; however, in the DAS <1.6 steered group, more patients achieved remission and drug-free remission.
引用
- Akdemir G, Markusse IM, Bergstra SA, et al. Comparison between low disease activity or DAS remission as treatment target in patients with early active rheumatoid arthritis. RMD Open. 2018. PMID: 29862045. doi:10.1136/rmdopen-2018-000649
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。